Australia
· Delayed Price · Currency is AUD Argent BioPharma Statistics
Total Valuation
ASX:RGT has a market cap or net worth of AUD 8.66 million. The enterprise value is 17.30 million.
| Market Cap | 8.66M |
| Enterprise Value | 17.30M |
Important Dates
The next estimated earnings date is Thursday, May 29, 2025.
| Earnings Date | May 29, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
ASX:RGT has 72.18 million shares outstanding. The number of shares has increased by 284.88% in one year.
| Current Share Class | 72.18M |
| Shares Outstanding | 72.18M |
| Shares Change (YoY) | +284.88% |
| Shares Change (QoQ) | -0.50% |
| Owned by Insiders (%) | 41.99% |
| Owned by Institutions (%) | 1.62% |
| Float | 27.70M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 29.28 |
| PB Ratio | -0.80 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -0.76 |
| EV / Sales | 58.46 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -1.55 |
Financial Position
The company has a current ratio of 0.16
| Current Ratio | 0.16 |
| Quick Ratio | 0.08 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.84 |
| Interest Coverage | -422.14 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -121.60% |
| Return on Invested Capital (ROIC) | -282.13% |
| Return on Capital Employed (ROCE) | 195.82% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.03 |
| Inventory Turnover | 0.86 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -68.42% in the last 52 weeks. The beta is 0.50, so ASX:RGT's price volatility has been lower than the market average.
| Beta (5Y) | 0.50 |
| 52-Week Price Change | -68.42% |
| 50-Day Moving Average | 0.15 |
| 200-Day Moving Average | 0.24 |
| Relative Strength Index (RSI) | 42.26 |
| Average Volume (20 Days) | 32,593 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, ASX:RGT had revenue of AUD 295,832 and -22.62 million in losses. Loss per share was -0.45.
| Revenue | 295,832 |
| Gross Profit | -375,940 |
| Operating Income | -19.84M |
| Pretax Income | -22.62M |
| Net Income | -22.62M |
| EBITDA | -18.81M |
| EBIT | -19.84M |
| Loss Per Share | -0.45 |
Balance Sheet
The company has 718,387 in cash and 9.35 million in debt, giving a net cash position of -8.63 million or -0.12 per share.
| Cash & Cash Equivalents | 718,387 |
| Total Debt | 9.35M |
| Net Cash | -8.63M |
| Net Cash Per Share | -0.12 |
| Equity (Book Value) | -10.88M |
| Book Value Per Share | -0.20 |
| Working Capital | -11.14M |
Cash Flow
In the last 12 months, operating cash flow was -11.03 million and capital expenditures -125,531, giving a free cash flow of -11.16 million.
| Operating Cash Flow | -11.03M |
| Capital Expenditures | -125,531 |
| Free Cash Flow | -11.16M |
| FCF Per Share | -0.15 |
Margins
| Gross Margin | -127.08% |
| Operating Margin | -6,705.93% |
| Pretax Margin | -7,644.93% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ASX:RGT does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -284.88% |
| Shareholder Yield | -284.88% |
| Earnings Yield | -261.10% |
| FCF Yield | -128.80% |
Stock Splits
The last stock split was on October 30, 2023. It was a reverse split with a ratio of 0.001.
| Last Split Date | Oct 30, 2023 |
| Split Type | Reverse |
| Split Ratio | 0.001 |
Scores
ASX:RGT has an Altman Z-Score of -89.9. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -89.9 |
| Piotroski F-Score | n/a |